12/08/2025
In this new edition of Retina Today, we dive into the drug-development pipeline — a true retina-therapeutics wish list.
This issue highlights 77 investigational therapies across wet/dry AMD, DME, and diabetic retinopathy, including 15 Phase 3 programs — with several expected to reach primary completion next year.
From reducing injection burden to offering options for anti-VEGF nonresponders, these emerging therapies bring real optimism. Keep an eye on frontrunners like KSI-301, EYP-1901, ABBV-RGX-314, ADVM-022, and vonaprument — the future of retina care is taking shape.
Dive into this new edition at RetinaToday.com